Edgewell Personal Care Announces Sale of Feminine Care Business to Essity for $340M
Edgewell Personal Care (NYSE: EPC) entered a definitive agreement to sell its Feminine Care business to Essity for $340 million, expected to close in Q1 2026 subject to regulatory approvals. The divested portfolio includes Playtex, Stayfree, Carefree and o.b. Edgewell plans to use net proceeds primarily to strengthen the balance sheet and invest in core businesses. The company will classify Feminine Care as discontinued operations beginning in Q1 fiscal 2026 and expects annualized benefits of $0.40–$0.50 in adjusted EPS and $35–$45 million in adjusted EBITDA, net of transition income.
Edgewell Personal Care (NYSE: EPC) ha stipulato un accordo definitivo per vendere la sua attività di Feminine Care a Essity per $340 million, con chiusura prevista nel Q1 2026 soggetto all'approvazioni regolamentari. Il portafoglio ceduto include Playtex, Stayfree, Carefree e o.b. Edgewell prevede di utilizzare i proventi netti principalmente per rafforzare il bilancio e investire nelle attività principali. L'azienda classificherà Feminine Care come operazioni discontinue a partire dal Q1 fiscal 2026 e prevede benefici annualizzati di $0.40–$0.50 per azione rettificata (EPS) e $35–$45 million di EBITDA rettificato, al netto dei ricavi di transizione.
Edgewell Personal Care (NYSE: EPC) ha llegado a un acuerdo definitivo para vender su negocio de Feminine Care a Essity por $340 millones, y se espera que la operación se cierre en el Q1 2026, sujeto a aprobaciones regulatorias. La cartera desinvertida incluye Playtex, Stayfree, Carefree y o.b. Edgewell planea utilizar las netas principalmente para fortalecer el balance y invertir en los negocios centrales. La compañía clasificará Feminine Care como operaciones discontinuadas a partir del Q1 fiscal 2026 y espera beneficios anualizados de $0.40–$0.50 por acción ajustada (EPS) y $35–$45 millones de EBITDA ajustado, neto de ingresos de transición.
Edgewell Personal Care (NYSE: EPC)가 Essity에 여성 관리 비즈니스를 $340 million에 매각하기로 확정 계약을 체결했으며, 규제 승인에 따라 2026년 1분기에 마감될 예정입니다. 매각 대상 포트폴리오는 Playtex, Stayfree, Carefree 및 o.b.를 포함합니다. Edgewell은 순수익금을 주로 재무상태를 강화하고 핵심 사업에 투자하는 데 사용할 계획입니다. 회사는 Q1 fiscal 2026부터 Feminine Care를 중단된 사업으로 분류하고, 조정된 EPS에서 연간 $0.40–$0.50의 이익과 조정된 EBITDA에서 $35–$45 million의 이익을 전환 소득을 차감한 상태로 기대합니다.
Edgewell Personal Care (NYSE: EPC) a conclu un accord définitif pour vendre son activité Feminine Care à Essity pour 340 millions de dollars, dont la clôture est prévue au premier trimestre 2026 sous réserve des approbations réglementaires. Le portefeuille cédé comprend Playtex, Stayfree, Carefree et o.b. Edgewell prévoit d'utiliser le produit net principalement pour renforcer le bilan et investir dans les activités principales. L'entreprise classera Feminine Care comme des opérations abandonnées à partir du Q1 fiscal 2026 et prévoit des avantages annuels de $0.40–$0.50 par action ajustée (EPS) et $35–$45 millions d'EBITDA ajusté, nets des revenus de transition.
Edgewell Personal Care (NYSE: EPC) hat eine endgültige Vereinbarung getroffen, ihr Feminine Care-Geschäft an Essity für $340 Millionen zu verkaufen, der Abschluss soll im Q1 2026 erfolgen, vorbehaltlich behördlicher Genehmigungen. Das veräußerte Portfolio umfasst Playtex, Stayfree, Carefree und o.b. Edgewell plant, den Nettobetrag hauptsächlich zu verwenden, um die Bilanz zu stärken und in Kernbereiche zu investieren. Das Unternehmen wird Feminine Care ab dem Q1 des Geschäftsjahres 2026 als stillgelegte Operationen einstufen und rechnet mit jährlichen Vorteilen von $0.40–$0.50 pro Aktie (bereinigt) und $35–$45 Millionen EBITDA (bereinigt), netto der Übergangs Einnahmen.
Edgewell Personal Care (NYSE: EPC) أبرمت اتفاقاً حاسماً لبيع نشاط العناية الأنثوية لشركة Essity مقابل $340 مليون، ومن المتوقع أن تتم الصفقة في الربع الأول من 2026 رهناً بموافقات تنظيمية. المحفظة المتخمة للصفقات تضم Playtex و Stayfree و Carefree و o.b. تخطط Edgewell لاستخدام العائدات الصافية أساساً لتعزيز الميزانية والاستثمار في الأعمال الأساسية. ستصنف الشركة العناية الأنثوية كعمليات متوقفة اعتباراً من الربع الأول من السنة المالية 2026 وتتوقع فوائد سنوية بقدر $0.40–$0.50 للسهم المعدل (EPS) و$35–$45 مليون من EBITDA المعدل، صافية من إيرادات الانتقال.
- Transaction value of $340 million
- Anticipated annualized adjusted EPS benefit of $0.40–$0.50
- Expected annualized adjusted EBITDA of $35–$45 million
- Proceeds intended to strengthen balance sheet
- Sale sharpens focus on core categories and growth
- Deal subject to regulatory approvals and closing conditions
- Edgewell expects stranded overhead costs in fiscal 2026
- Timing risk: closing expected in Q1 2026 but not guaranteed
Insights
Sale refocuses Edgewell on core categories while transferring established feminine brands to Essity.
Edgewell sells its Feminine Care business, including Playtex, Stayfree, Carefree, and o.b., to Essity for
Key dependencies and risks include receipt of required regulatory approvals and the successful execution of transition services; the company discloses it will provide certain services post-close and may incur stranded overhead in fiscal
Proceeds aim to strengthen the balance sheet, but the divestiture reduces recurring adjusted EBITDA.
Management intends to use net proceeds primarily to strengthen the balance sheet and invest in core businesses; the company expects an annualized adjusted EBITDA impact of
Watch for the actual net proceeds after taxes and transaction costs, the timing of cash receipt at closing (expected
Transaction streamlines Edgewell's portfolio and allows the personal care brand to focus on areas of competitive leadership
The transaction is expected to close in the first quarter of calendar 2026, subject to customary closing conditions, including the receipt of required regulatory approvals. Edgewell's feminine care business includes Playtex®, Stayfree®, Carefree® and o.b.®. Edgewell intends to use the net proceeds from the sale, after taxes and transaction costs, primarily to strengthen its balance sheet while continuing to invest in the long-term growth of its core businesses.
"This transaction marks a pivotal step in Edgewell's transformation. By selling our Feminine Care business to Essity, we are sharpening our focus on our core categories, strengthening our financial position, and positioning Edgewell for sustainable, long-term growth," said Edgewell President and CEO Rod Little. "This is a win for our shareholders who will benefit from a more agile and focused company; for our customers, who will continue to receive innovative products and dedicated service; and for our employees, who will have new opportunities for growth and success with Essity, a global leader in health and hygiene."
"I'm excited to further grow these well-known brands by welcoming them into our bold and purpose-driven feminine care business. With this acquisition we are building a stronger personal care business in
Edgewell will work closely with Essity to ensure a smooth transition for employees, customers, and consumers of the Feminine Care business. Edgewell has agreed to provide Essity with certain services to support the transition of the business following the completion of the transaction.
Beginning in the first quarter of fiscal 2026, Edgewell will classify the Feminine Care business as discontinued operations. Following the transaction, Edgewell expects to incur certain stranded overhead costs, which for fiscal 2026, will be substantially offset by income generated from the provision of transition support services to Essity. For context, the Company expects the impact of Feminine Care business sale on an annualized basis to be approximately
Advisors
Perella Weinberg Partners LP is serving as financial advisor to Edgewell. Latham & Watkins LLP is serving as legal advisor to Edgewell.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the anticipated timeline for closing of the transaction, our anticipated uses of net proceeds from the transaction, anticipated benefits of the transaction to us and our stakeholders, entry into and the obligations under the transition services agreement following the transaction, and our strategy, future financial results, and competitive position. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the risk that the parties may be unable to close the transaction on anticipated timelines or at all; the failure to obtain regulatory approvals or satisfy other conditions to closing required in connection with the transaction; costs associated with the transaction and the potential that it may not have the anticipated impact on our business; the risk that disruptions from the transaction will harm business plans and operations; our ability to compete in products and prices, as well as costs, in an intensely competitive industry; the loss of any of our principal customers or changes in the policies of our principal customers; our inability to design and execute a successful omnichannel strategy; our ability to attract, retain and develop key personnel; fluctuations in the price and supply of raw materials and costs of labor, warehousing and transportation; as well as the other factors described in our Annual Report on Form 10-K for the year ended September 30, 2024, as will be updated in our Annual Report on Form 10-K for the year ended September 30, 2025 and as may be further updated in the Company's other filings with the Securities and Exchange Commission. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
About Edgewell Personal Care
Edgewell is a leading pure-play consumer products company with an attractive, diversified portfolio of established brand names such as Schick®, Wilkinson Sword® and Billie® men's and women's shaving systems and disposable razors; Edge and Skintimate® shave preparations; Playtex®, Stayfree®, Carefree® and o.b.® feminine care products; Banana Boat®, Hawaiian Tropic®, Bulldog®, Jack Black®, and CREMO® sun and skin care products; and Wet Ones® products. The Company has a broad global footprint and operates in more than 50 markets, including the
About Essity
Essity is a global, leading hygiene and health company with products, solutions and services used by a billion people around the world every day. Essity's purpose is to break barriers to well-being for the benefit of consumers, patients, caregivers, customers and society. Sales are conducted in approximately 150 countries under the leading global brands TENA and Tork, and other strong brands such as Actimove, Cutimed, JOBST, Knix, Leukoplast, Libero, Libresse, Lotus, Modibodi, Nosotras, Saba, Tempo, TOM Organic and Zewa. In 2024, Essity had net sales of approximately
View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewell-personal-care-announces-sale-of-feminine-care-business-to-essity-for-340m-302613650.html
SOURCE Edgewell Personal Care Company
FAQ
What did Edgewell (EPC) announce on November 12, 2025 about its feminine care business?
How will the sale affect Edgewell's earnings per share (EPC)?
What brands are included in the Edgewell feminine care sale (EPC)?
When will Edgewell (EPC) classify the feminine care business as discontinued operations?
What is the expected adjusted EBITDA impact from the Edgewell (EPC) sale?
Will Edgewell (EPC) provide transition support after the sale closes?
